Videos

The discussion concludes with examination of recent research developments, particularly the CROWN trial's 7-year follow-up data presented at the American Society of Clinical Oncology meeting. Dr. Florez explains that this trial has changed ALK-positive treatment paradigms by demonstrating unprecedented durability of response with lorlatinib compared to previous standard crizotinib therapy.

The segment explores concepts of living well with cancer, advocacy, and community building for young patients facing long-term therapy. Dr. Florez notes that current reality for many young patients with ALK-positive disease involves years rather than months of survival, fundamentally changing perspectives on living with versus dying from cancer.